Not All WHO-Recommended First-Line Regimens Are Equal

The efficacy of tenofovir + 3TC + nevirapine is questionable, according to a systematic review presented at IAS 2011.

In 2010, the WHO added four new antiretroviral regimens to its list of recommended first-line therapies: tenofovir + 3TC + nevirapine, tenofovir + 3TC + efavirenz, tenofovir + FTC + nevirapine, and tenofovir + FTC + efavirenz. Now, a systematic review, presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention [Tang M et al. Abstract WEPDB0103], has cast doubt on the efficacy of one of these regimens.

Thirty prospective and retrospective studies were included in the review and provided substantial data to support the efficacy of tenofovir + FTC + nevirapine and tenofovir + 3TC (or FTC) + efavirenz. However, there were only three studies on tenofovir + 3TC + nevirapine, and two of them showed that the regimen was inferi…

Author

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Not All WHO-Recommended First-Line Regimens Are Equal

Topics

Author